{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:27:02Z","timestamp":1790612822610,"version":"4.1.0"},"reference-count":164,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.bbr.2020.113004","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T11:19:30Z","timestamp":1605266370000},"page":"113004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Molecular imaging of schizophrenia: Neurochemical findings in a heterogeneous and evolving disorder"],"prefix":"10.1016","volume":"398","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0257-9621","authenticated-orcid":false,"given":"Paul","family":"Cumming","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anissa","family":"Abi-Dargham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Gr\u00fcnder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.bbr.2020.113004_bib0005","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0006-3223(99)00018-9","article-title":"MRI anatomy of schizophrenia","volume":"45","author":"McCarley","year":"1999","journal-title":"Biol. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.bbr.2020.113004_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-9964(01)00163-3","article-title":"A review of MRI findings in schizophrenia","volume":"49","author":"Shenton","year":"2001","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.bbr.2020.113004_bib0015","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11064-018-2521-z","article-title":"Magnetic resonance spectroscopy in schizophrenia: evidence for glutamatergic dysfunction and impaired energy metabolism","volume":"44","author":"Duarte","year":"2019","journal-title":"Neurochem. Res."},{"issue":"5480","key":"10.1016\/j.bbr.2020.113004_bib0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/bmj.1.5480.119","article-title":"Pink spot in schizophrenia","volume":"1","year":"1966","journal-title":"Br. Med. J."},{"issue":"5056","key":"10.1016\/j.bbr.2020.113004_bib0025","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/2111404a0","article-title":"The \"pink spot\" and schizophrenia","volume":"211","author":"Boulton","year":"1966","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bbr.2020.113004_bib0030","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/ajp.127.5.611","article-title":"The \u201cpink spot,\u201d 3,4-dimethoxyphenylethylamine, common tea, and schizophrenia","volume":"127","author":"Stabenau","year":"1970","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.bbr.2020.113004_bib0035","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s13139-010-0028-x","article-title":"Is this Red Spot the Blue Spot (locus ceruleus)?","volume":"44","author":"Choe","year":"2010","journal-title":"Nucl. Med. Mol. Imaging"},{"issue":"2","key":"10.1016\/j.bbr.2020.113004_bib0040","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/schbul\/14.2.169","article-title":"From syndrome to illness: delineating the pathophysiology of schizophrenia with PET","volume":"14","author":"Cohen","year":"1988","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.bbr.2020.113004_bib0045","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/schbul\/14.2.157","article-title":"Speculation on the meaning of cerebral metabolic hypofrontality in schizophrenia","volume":"14","author":"Weinberger","year":"1988","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.bbr.2020.113004_bib0050","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1600-0447.2004.00376.x","article-title":"Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies","volume":"110","author":"Hill","year":"2004","journal-title":"Acta Psychiatr. Scand."},{"issue":"5","key":"10.1016\/j.bbr.2020.113004_bib0055","first-page":"663","article-title":"Correlational methods for determining regional coupling of cerebral glucose metabolism: a pilot study","volume":"19","author":"Clark","year":"1984","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.bbr.2020.113004_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000119241","article-title":"Correlational patterns of cerebral glucose metabolism in never-medicated schizophrenics","volume":"33","author":"Katz","year":"1996","journal-title":"Neuropsychobiology"},{"issue":"9","key":"10.1016\/j.bbr.2020.113004_bib0065","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1176\/ajp.150.9.1325","article-title":"Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients","volume":"150","author":"Siegel","year":"1993","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.bbr.2020.113004_bib0070","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1176\/appi.ajp.159.2.227","article-title":"A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography","volume":"159","author":"Potkin","year":"2002","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.bbr.2020.113004_bib0075","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1528-1157.1969.tb03853.x","article-title":"Psychosis and temporal lobe epilepsy. A controlled investigation","volume":"10","author":"Flor-Henry","year":"1969","journal-title":"Epilepsia"},{"issue":"5934","key":"10.1016\/j.bbr.2020.113004_bib0080","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/305527a0","article-title":"Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia","volume":"305","author":"Reynolds","year":"1983","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bbr.2020.113004_bib0085","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000339562","article-title":"Gender and rapid alterations of hemispheric dominance during planning","volume":"66","author":"Schuepbach","year":"2012","journal-title":"Neuropsychobiology"},{"issue":"4","key":"10.1016\/j.bbr.2020.113004_bib0090","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/oxfordjournals.schbul.a033505","article-title":"Reduced frontal functional asymmetry in schizophrenia during a cued continuous performance test assessed with near-infrared spectroscopy","volume":"26","author":"Fallgatter","year":"2000","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.bbr.2020.113004_bib0095","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1017\/S0033291700029032","article-title":"Patterns of cortical activity in schizophrenia","volume":"24","author":"Schroeder","year":"1994","journal-title":"Psychol. Med."},{"issue":"2","key":"10.1016\/j.bbr.2020.113004_bib0100","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1176\/appi.ajp.161.2.305","article-title":"Abnormal glucose metabolism in the mediodorsal nucleus of the thalamus in schizophrenia","volume":"161","author":"Hazlett","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbr.2020.113004_bib0105","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fnsys.2013.00037","article-title":"What does the mediodorsal thalamus do?","volume":"7","author":"Mitchell","year":"2013","journal-title":"Front. Syst. Neurosci."},{"issue":"6034","key":"10.1016\/j.bbr.2020.113004_bib0110","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/317246a0","article-title":"Positron emission tomography after MPTP: observations relating to the cause of Parkinson\u2019s disease","volume":"317","author":"Calne","year":"1985","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.bbr.2020.113004_bib0115","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/0024-3205(86)90403-0","article-title":"Determination of plasma [18F]-6-fluorodopa during positron emission tomography: elimination and metabolism in carbidopa treated subjects","volume":"39","author":"Boyes","year":"1986","journal-title":"Life Sci."},{"issue":"4","key":"10.1016\/j.bbr.2020.113004_bib0120","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/ana.410260407","article-title":"Nigrostriatal function in humans studied with positron emission tomography","volume":"26","author":"Martin","year":"1989","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.bbr.2020.113004_bib0125","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1471-4159.1987.tb04135.x","article-title":"The metabolism of [18F]6-fluoro-L-3,4-dihydroxyphenylalanine in the hooded rat","volume":"48","author":"Cumming","year":"1987","journal-title":"J. Neurochem."},{"issue":"6","key":"10.1016\/j.bbr.2020.113004_bib0130","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/1073858409338217","article-title":"PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches","volume":"15","author":"Kumakura","year":"2009","journal-title":"Neuroscientist"},{"issue":"24","key":"10.1016\/j.bbr.2020.113004_bib0135","doi-asserted-by":"crossref","first-page":"11651","DOI":"10.1073\/pnas.91.24.11651","article-title":"Elevated dopa decarboxylase activity in living brain of patients with psychosis","volume":"91","author":"Reith","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.bbr.2020.113004_bib0140","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/archgenpsychiatry.2012.169","article-title":"The nature of dopamine dysfunction in schizophrenia and what this means for treatment","volume":"69","author":"Howes","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3","key":"10.1016\/j.bbr.2020.113004_bib0145","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nn804","article-title":"Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia","volume":"5","author":"Meyer-Lindenberg","year":"2002","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bbr.2020.113004_bib0150","doi-asserted-by":"crossref","DOI":"10.1093\/schbul\/sbaa055","article-title":"Striatal dopamine and reward prediction error signaling in unmedicated schizophrenia patients","author":"Katthagen","year":"2020","journal-title":"Schizophr. Bull."},{"issue":"30","key":"10.1016\/j.bbr.2020.113004_bib0155","doi-asserted-by":"crossref","first-page":"8080","DOI":"10.1523\/JNEUROSCI.0805-07.2007","article-title":"Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa\/positron emission tomography study","volume":"27","author":"Kumakura","year":"2007","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.bbr.2020.113004_bib0160","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.neuroimage.2005.11.014","article-title":"Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge","volume":"30","author":"Vernaleken","year":"2006","journal-title":"Neuroimage"},{"issue":"4","key":"10.1016\/j.bbr.2020.113004_bib0165","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/sj.npp.1300103","article-title":"Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo","volume":"28","author":"Grunder","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.bbr.2020.113004_bib0170","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0166-2236(96)10064-3","article-title":"Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs","volume":"20","author":"Grace","year":"1997","journal-title":"Trends Neurosci."},{"issue":"6","key":"10.1016\/j.bbr.2020.113004_bib0175","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/brain\/awz093","article-title":"Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms","volume":"142","author":"Avram","year":"2019","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.bbr.2020.113004_bib0180","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/brain\/awz133","article-title":"The downside of downregulation","volume":"142","author":"Grunder","year":"2019","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.bbr.2020.113004_bib0185","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.biopsych.2018.07.003","article-title":"The effects of antipsychotic treatment on presynaptic dopamine synthesis capacity in first-episode psychosis: a positron emission tomography study","volume":"85","author":"Jauhar","year":"2019","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.bbr.2020.113004_bib0190","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0006-3223(99)00067-0","article-title":"Increased dopamine transmission in schizophrenia: relationship to illness phases","volume":"46","author":"Laruelle","year":"1999","journal-title":"Biol. Psychiatry"},{"issue":"12","key":"10.1016\/j.bbr.2020.113004_bib0195","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1176\/appi.ajp.2011.11010160","article-title":"Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study","volume":"168","author":"Howes","year":"2011","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.bbr.2020.113004_bib0200","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.biopsych.2012.11.017","article-title":"Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort","volume":"74","author":"Egerton","year":"2013","journal-title":"Biol. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.bbr.2020.113004_bib0205","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.schres.2016.06.005","article-title":"Adversity in childhood linked to elevated striatal dopamine function in adulthood","volume":"176","author":"Egerton","year":"2016","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.bbr.2020.113004_bib0210","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.biopsych.2007.04.017","article-title":"Striatal dopamine synthesis in first-degree relatives of patients with schizophrenia","volume":"63","author":"Huttunen","year":"2008","journal-title":"Biol. Psychiatry"},{"issue":"11","key":"10.1016\/j.bbr.2020.113004_bib0215","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1176\/appi.ajp.2012.12010144","article-title":"Dopamine synthesis capacity in patients with treatment-resistant schizophrenia","volume":"169","author":"Demjaha","year":"2012","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.bbr.2020.113004_bib0220","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/npp.2016.258","article-title":"Presynaptic dopamine capacity in patients with treatment-resistant schizophrenia taking clozapine: an [(18)F]DOPA PET study","volume":"42","author":"Kim","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2020.113004_bib0225","article-title":"A potential biomarker for treatment stratification in psychosis: evaluation of an [(18)F] FDOPA PET imaging approach","author":"Veronese","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.bbr.2020.113004_bib0230","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/schbul\/sbw192","article-title":"Striatal and extrastriatal dopamine transporter availability in schizophrenia and its clinical correlates: a voxel-based and high-resolution PET study","volume":"43","author":"Artiges","year":"2017","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.bbr.2020.113004_bib0235","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2019.07.008","article-title":"Heterogeneity of striatal dopamine function in schizophrenia: meta-analysis of variance","volume":"87","author":"Brugger","year":"2020","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.bbr.2020.113004_bib0240","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.neuroimage.2005.09.044","article-title":"Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: a multi-tracer PET study","volume":"30","author":"Doudet","year":"2006","journal-title":"Neuroimage"},{"key":"10.1016\/j.bbr.2020.113004_bib0245","article-title":"A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter","author":"Amato","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bbr.2020.113004_bib0250","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fpsyt.2019.00314","article-title":"Hypofunctional dopamine uptake and antipsychotic treatment-resistant schizophrenia","volume":"10","author":"Amato","year":"2019","journal-title":"Front. Psychiatry"},{"issue":"4783","key":"10.1016\/j.bbr.2020.113004_bib0255","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1126\/science.2878495","article-title":"Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics","volume":"234","author":"Wong","year":"1986","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bbr.2020.113004_bib0260","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0925-4927(95)02732-D","article-title":"No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N-methylspiperone","volume":"61","author":"Nordstrom","year":"1995","journal-title":"Psychiatry Res."},{"issue":"3","key":"10.1016\/j.bbr.2020.113004_bib0265","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1001\/archpsyc.1990.01810150013003","article-title":"D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride","volume":"47","author":"Farde","year":"1990","journal-title":"Arch. Gen. Psychiatry"},{"issue":"6","key":"10.1016\/j.bbr.2020.113004_bib0270","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1192\/bjp.bp.113.132308","article-title":"Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies","volume":"204","author":"Kambeitz","year":"2014","journal-title":"Br. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.bbr.2020.113004_bib0275","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00008877-200109000-00007","article-title":"Dopamine receptors in the brains of schizophrenia patients: a meta-analysis of the findings","volume":"12","author":"Kestler","year":"2001","journal-title":"Behav. Pharmacol."},{"issue":"5","key":"10.1016\/j.bbr.2020.113004_bib0280","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/00004647-200205000-00011","article-title":"Specific binding of [(11)C]raclopride and N-[(3)H]propyl-norapomorphine to dopamine receptors in living mouse striatum: occupancy by endogenous dopamine and guanosine triphosphate-free G protein","volume":"22","author":"Cumming","year":"2002","journal-title":"J. Cereb. Blood Flow Metab."},{"issue":"1","key":"10.1016\/j.bbr.2020.113004_bib0285","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/syn.20706","article-title":"MDMA-evoked changes in the binding of dopamine D(2) receptor ligands in striatum of rats with unilateral serotonin depletion","volume":"64","author":"Ostergaard","year":"2010","journal-title":"Synapse"},{"issue":"17","key":"10.1016\/j.bbr.2020.113004_bib0290","doi-asserted-by":"crossref","first-page":"9235","DOI":"10.1073\/pnas.93.17.9235","article-title":"Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects","volume":"93","author":"Laruelle","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.bbr.2020.113004_bib0295","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1176\/ajp.155.6.761","article-title":"Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort","volume":"155","author":"Abi-Dargham","year":"1998","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.bbr.2020.113004_bib0300","first-page":"293","article-title":"Elevated striatal dopamine function in immigrants and their children: a risk mechanism for psychosis","volume":"43","author":"Egerton","year":"2017","journal-title":"Schizophr. Bull."},{"issue":"8","key":"10.1016\/j.bbr.2020.113004_bib0305","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1038\/sj.npp.1301597","article-title":"Stress-induced dopamine release in humans at risk of psychosis: a [11C]raclopride PET study","volume":"33","author":"Soliman","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.bbr.2020.113004_bib0310","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1001\/archpsyc.63.12.1386","article-title":"Modeling sensitization to stimulants in humans: an [11C]raclopride\/positron emission tomography study in healthy men","volume":"63","author":"Boileau","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.bbr.2020.113004_bib0315","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41398-019-0681-5","article-title":"On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D2\/3 receptor agonist radioligand study","volume":"10","author":"Weidenauer","year":"2020","journal-title":"Transl. Psychiatry"},{"issue":"4","key":"10.1016\/j.bbr.2020.113004_bib0320","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/npp.2008.199","article-title":"The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study","volume":"34","author":"Graff-Guerrero","year":"2009","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.bbr.2020.113004_bib0325","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.biopsych.2017.11.032","article-title":"Amphetamine-induced striatal dopamine release measured with an agonist radiotracer in schizophrenia","volume":"83","author":"Frankle","year":"2018","journal-title":"Biol. Psychiatry"},{"issue":"14","key":"10.1016\/j.bbr.2020.113004_bib0330","doi-asserted-by":"crossref","first-page":"8104","DOI":"10.1073\/pnas.97.14.8104","article-title":"Increased baseline occupancy of D2 receptors by dopamine in schizophrenia","volume":"97","author":"Abi-Dargham","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.bbr.2020.113004_bib0335","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0893-133X(01)00263-9","article-title":"Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging","volume":"25","author":"Voruganti","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2020.113004_bib0340","doi-asserted-by":"crossref","first-page":"107591","DOI":"10.1016\/j.neuropharm.2019.03.034","article-title":"What proportion of striatal D2 receptors are occupied by endogenous dopamine at baseline? A meta-analysis with implications for understanding antipsychotic occupancy","volume":"163","author":"Caravaggio","year":"2020","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.bbr.2020.113004_bib0345","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/npp.2015.296","article-title":"Imaging agonist-induced D2\/D3 receptor desensitization and internalization in vivo with PET\/fMRI","volume":"41","author":"Sander","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.bbr.2020.113004_bib0350","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/mp.2017.107","article-title":"PET imaging of dopamine-D2 receptor internalization in schizophrenia","volume":"23","author":"Weinstein","year":"2018","journal-title":"Mol. Psychiatry"},{"issue":"12","key":"10.1016\/j.bbr.2020.113004_bib0355","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1017\/S0033291717000563","article-title":"Stability and development of psychotic symptoms and the use of antipsychotic medication - long-term follow-up","volume":"47","author":"Gotfredsen","year":"2017","journal-title":"Psychol. Med."},{"issue":"9","key":"10.1016\/j.bbr.2020.113004_bib0360","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/syn.20916","article-title":"Absolute abundances and affinity states of dopamine receptors in mammalian brain: a review","volume":"65","author":"Cumming","year":"2011","journal-title":"Synapse"},{"issue":"7","key":"10.1016\/j.bbr.2020.113004_bib0365","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/ijnp\/pyz017","article-title":"D1-dopamine receptor availability in first-episode neuroleptic naive psychosis patients","volume":"22","author":"Stenkrona","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"10","key":"10.1016\/j.bbr.2020.113004_bib0370","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1176\/ajp.2006.163.10.1747","article-title":"Brain dopamine d1 receptors in twins discordant for schizophrenia","volume":"163","author":"Hirvonen","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"21\u201322","key":"10.1016\/j.bbr.2020.113004_bib0375","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.lfs.2010.03.018","article-title":"Decreased binding of [11C]NNC112 and [11C]SCH23390 in patients with chronic schizophrenia","volume":"86","author":"Kosaka","year":"2010","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.bbr.2020.113004_bib0380","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00213-013-3026-8","article-title":"In vivo binding of the dopamine-1 receptor PET tracers [(1)(1)C]NNC112 and [(1)(1)C]SCH23390: a comparison study in individuals with schizophrenia","volume":"228","author":"Poels","year":"2013","journal-title":"Psychopharmacology (Berl.)"},{"issue":"9","key":"10.1016\/j.bbr.2020.113004_bib0385","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/sj.npp.1300224","article-title":"Dopamine depletion and in vivo binding of PET D1 receptor radioligands: implications for imaging studies in schizophrenia","volume":"28","author":"Guo","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.bbr.2020.113004_bib0390","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1177\/0269881111409265","article-title":"Increased prefrontal cortical D(1) receptors in drug naive patients with schizophrenia: a PET study with [(1)(1)C]NNC112","volume":"26","author":"Abi-Dargham","year":"2012","journal-title":"J. Psychopharmacol. (Oxford)"},{"issue":"9","key":"10.1016\/j.bbr.2020.113004_bib0395","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1523\/JNEUROSCI.22-09-03708.2002","article-title":"Prefrontal dopamine D1 receptors and working memory in schizophrenia","volume":"22","author":"Abi-Dargham","year":"2002","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.bbr.2020.113004_bib0400","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.neuroimage.2011.04.047","article-title":"Relationship of dopamine D1 receptor binding in striatal and extrastriatal regions to cognitive functioning in healthy humans","volume":"57","author":"Karlsson","year":"2011","journal-title":"Neuroimage"},{"issue":"6","key":"10.1016\/j.bbr.2020.113004_bib0405","doi-asserted-by":"crossref","first-page":"e1501672","DOI":"10.1126\/sciadv.1501672","article-title":"Dopamine D1 signaling organizes network dynamics underlying working memory","volume":"2","author":"Roffman","year":"2016","journal-title":"Sci. Adv."},{"issue":"11","key":"10.1016\/j.bbr.2020.113004_bib0410","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1101\/lm.031971.113","article-title":"Dopamine D1 sensitivity in the prefrontal cortex predicts general cognitive abilities and is modulated by working memory training","volume":"20","author":"Wass","year":"2013","journal-title":"Learn. Mem."},{"issue":"1","key":"10.1016\/j.bbr.2020.113004_bib0415","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/npp.2008.166","article-title":"The role of imaging in proof of concept for CNS drug discovery and development","volume":"34","author":"Wong","year":"2009","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.bbr.2020.113004_bib0420","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0031-1286282","article-title":"Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging","volume":"44","author":"Grunder","year":"2011","journal-title":"Pharmacopsychiatry"},{"issue":"7","key":"10.1016\/j.bbr.2020.113004_bib0425","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects","volume":"49","author":"Farde","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"issue":"6","key":"10.1016\/j.bbr.2020.113004_bib0430","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1176\/ajp.156.6.869","article-title":"Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients","volume":"156","author":"Nyberg","year":"1999","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.bbr.2020.113004_bib0435","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd2806","article-title":"The\u2019 atypicality\u2019 of antipsychotics: a concept re-examined and re-defined","volume":"8","author":"Grunder","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.bbr.2020.113004_bib0440","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/sj.npp.1300931","article-title":"The striatal and extrastriatal D2\/D3 receptor-binding profile of clozapine in patients with schizophrenia","volume":"31","author":"Grunder","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.bbr.2020.113004_bib0445","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/archpsyc.60.10.974","article-title":"Mechanism of new antipsychotic medications: occupancy is not just antagonism","volume":"60","author":"Grunder","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"issue":"8","key":"10.1016\/j.bbr.2020.113004_bib0450","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1176\/appi.ajp.2008.07101574","article-title":"Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study","volume":"165","author":"Grunder","year":"2008","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.bbr.2020.113004_bib0455","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/s41386-019-0590-6","article-title":"A positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, and serotonin reuptake transporters in subjects with schizophrenia","volume":"45","author":"Girgis","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"19\u201320","key":"10.1016\/j.bbr.2020.113004_bib0460","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1007\/s00213-016-4382-y","article-title":"Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3\/D2 receptor ligand [(11)C]-(+)-PHNO","volume":"233","author":"Girgis","year":"2016","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.bbr.2020.113004_bib0465","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nicl.2016.06.007","article-title":"Occupancy of pramipexole (Sifrol) at cerebral dopamine D2\/3 receptors in Parkinson\u2019s disease patients","volume":"12","author":"Deutschlander","year":"2016","journal-title":"Neuroimage Clin."},{"issue":"3","key":"10.1016\/j.bbr.2020.113004_bib0470","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF02251280","article-title":"5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone","volume":"110","author":"Nyberg","year":"1993","journal-title":"Psychopharmacology (Berl.)"},{"issue":"1","key":"10.1016\/j.bbr.2020.113004_bib0475","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s002130000679","article-title":"Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study","volume":"156","author":"Lavalaye","year":"2001","journal-title":"Psychopharmacology (Berl.)"},{"issue":"3","key":"10.1016\/j.bbr.2020.113004_bib0480","doi-asserted-by":"crossref","first-page":"111","DOI":"10.9758\/cpn.2011.9.3.111","article-title":"Occupancy of alpha7 nicotinic acetylcholine receptors in the brain by tropisetron: a positron emission tomography study using [(11)C]CHIBA-1001 in healthy human subjects","volume":"9","author":"Ishikawa","year":"2011","journal-title":"Clin. Psychopharmacol. Neurosci."},{"issue":"3","key":"10.1016\/j.bbr.2020.113004_bib0485","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF01276538","article-title":"Evidence for biochemical heterogeneity in schizophrenia: a multivariate study of monoaminergic indices in human post-mortal brain tissue","volume":"98","author":"Hansson","year":"1994","journal-title":"J. Neural Transm. Gen. Sect."},{"issue":"5","key":"10.1016\/j.bbr.2020.113004_bib0490","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/jnc.12848","article-title":"Measuring effects of MDMA (ecstasy) abuse on the rate of cerebral serotonin synthesis","volume":"131","author":"Cumming","year":"2014","journal-title":"J. Neurochem."},{"issue":"5","key":"10.1016\/j.bbr.2020.113004_bib0495","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0006-3223(99)00257-7","article-title":"Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT","volume":"47","author":"Laruelle","year":"2000","journal-title":"Biol. Psychiatry"},{"issue":"12","key":"10.1016\/j.bbr.2020.113004_bib0500","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.biopsych.2005.02.028","article-title":"Serotonin transporter availability in patients with schizophrenia: a positron emission tomography imaging study with [11C]DASB","volume":"57","author":"Frankle","year":"2005","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.bbr.2020.113004_bib0505","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pscychresns.2014.10.022","article-title":"Serotonin transporter availability in thalamic subregions in schizophrenia: a study using 7.0-T MRI with [(11)C]DASB high-resolution PET","volume":"231","author":"Kim","year":"2015","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.bbr.2020.113004_bib0510","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.schres.2016.10.020","article-title":"Altered interregional correlations between serotonin transporter availability and cerebral glucose metabolism in schizophrenia: a high-resolution PET study using [(11)C]DASB and [(18)F]FDG","volume":"182","author":"Kim","year":"2017","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.bbr.2020.113004_bib0515","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0893-133X(98)00108-0","article-title":"5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [11C]raclopride","volume":"20","author":"Vollenweider","year":"1999","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.bbr.2020.113004_bib0520","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0920-9964(98)00014-0","article-title":"No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET","volume":"31","author":"Trichard","year":"1998","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.bbr.2020.113004_bib0525","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1176\/ajp.156.1.72","article-title":"Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic-naive patients and normal subjects","volume":"156","author":"Lewis","year":"1999","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.bbr.2020.113004_bib0530","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0165-1781(00)00198-0","article-title":"A voxel-by-voxel analysis of [18F]setoperone PET data shows no substantial serotonin 5-HT(2A) receptor changes in schizophrenia","volume":"99","author":"Verhoeff","year":"2000","journal-title":"Psychiatry Res."},{"issue":"6","key":"10.1016\/j.bbr.2020.113004_bib0535","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1176\/appi.ajp.157.6.1016","article-title":"Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: A PET study using [(18)F]setoperone","volume":"157","author":"Ngan","year":"2000","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.bbr.2020.113004_bib0540","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00213-007-0921-x","article-title":"5-HT2A receptor density is decreased in the at-risk mental state","volume":"195","author":"Hurlemann","year":"2008","journal-title":"Psychopharmacology (Berl.)"},{"issue":"10","key":"10.1016\/j.bbr.2020.113004_bib0545","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1038\/sj.npp.1301656","article-title":"Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients","volume":"33","author":"Erritzoe","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.bbr.2020.113004_bib0550","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/archgenpsychiatry.2009.176","article-title":"Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia","volume":"67","author":"Rasmussen","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"issue":"8","key":"10.1016\/j.bbr.2020.113004_bib0555","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.euroneuro.2012.10.006","article-title":"Dysregulated 5-HT(2A) receptor binding in postmortem frontal cortex of schizophrenic subjects","volume":"23","author":"Muguruza","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"21","key":"10.1016\/j.bbr.2020.113004_bib0560","doi-asserted-by":"crossref","first-page":"5353","DOI":"10.1016\/j.bmc.2016.08.056","article-title":"Convergent (18)F-labeling and evaluation of N-benzyl-phenethylamines as 5-HT2A receptor PET ligands","volume":"24","author":"Petersen","year":"2016","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.bbr.2020.113004_bib0565","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/JCP.0b013e31827b97a6","article-title":"Effects of aripiprazole, risperidone, and olanzapine on 5-HT1A receptors in patients with schizophrenia","volume":"33","author":"Lerond","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.bbr.2020.113004_bib0570","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00213-011-2343-z","article-title":"Occupancy of dopamine D(2) and D(3) and serotonin 5-HT(1)A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography","volume":"218","author":"Seneca","year":"2011","journal-title":"Psychopharmacology (Berl.)"},{"issue":"2","key":"10.1016\/j.bbr.2020.113004_bib0575","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00213-006-0543-8","article-title":"Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [11C]WAY 100635","volume":"189","author":"Frankle","year":"2006","journal-title":"Psychopharmacology (Berl.)"},{"issue":"6","key":"10.1016\/j.bbr.2020.113004_bib0580","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/archpsyc.59.6.514","article-title":"Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635","volume":"59","author":"Tauscher","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"issue":"5","key":"10.1016\/j.bbr.2020.113004_bib0585","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.biopsych.2003.11.016","article-title":"Decreased 5-HT1A receptor binding in amygdala of schizophrenia","volume":"55","author":"Yasuno","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbr.2020.113004_bib0590","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.schres.2017.03.047","article-title":"Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the \u201cself-medication\u201d hypothesis in schizophrenia","volume":"194","author":"Boggs","year":"2018","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.bbr.2020.113004_bib0595","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1176\/appi.ajp.2011.11020189","article-title":"Lower ss2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia","volume":"169","author":"D\u2019Souza","year":"2012","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.bbr.2020.113004_bib0600","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/syn.21520","article-title":"Positron emission tomography experience with 2-[(1)(8)F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[(1)(8)F]FA) in the living human brain of smokers with paranoid schizophrenia","volume":"66","author":"Brasic","year":"2012","journal-title":"Synapse"},{"issue":"7","key":"10.1016\/j.bbr.2020.113004_bib0605","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/ijnp\/pyy021","article-title":"Brain PET imaging of alpha7-nAChR with [18F]ASEM: reproducibility, occupancy, receptor density, and changes in schizophrenia","volume":"21","author":"Wong","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.bbr.2020.113004_bib0610","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.neubiorev.2015.05.011","article-title":"The muscarinic system, cognition and schizophrenia","volume":"55","author":"Carruthers","year":"2015","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"9","key":"10.1016\/j.bbr.2020.113004_bib0615","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.euroneuro.2017.06.014","article-title":"The effect of the muscarinic M1 receptor antagonist biperiden on cognition in medication free subjects with psychosis","volume":"27","author":"Vingerhoets","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"10","key":"10.1016\/j.bbr.2020.113004_bib0620","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/ijnp\/pyz045","article-title":"Widespread changes in positive allosteric modulation of the muscarinic M1 receptor in some participants with schizophrenia","volume":"22","author":"Hopper","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.bbr.2020.113004_bib0625","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1176\/appi.ajp.160.1.118","article-title":"In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia","volume":"160","author":"Raedler","year":"2003","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.bbr.2020.113004_bib0630","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/sj.npp.1300210","article-title":"Central muscarinic acetylcholine receptor availability in patients treated with clozapine","volume":"28","author":"Raedler","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2020.113004_bib0635","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.nicl.2018.02.030","article-title":"Relationship between muscarinic M1 receptor binding and cognition in medication-free subjects with psychosis","volume":"18","author":"Bakker","year":"2018","journal-title":"Neuroimage Clin."},{"key":"10.1016\/j.bbr.2020.113004_bib0640","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.119.235143","article-title":"Evaluation of (11)C-NR2B-SMe and its enantiomers as PET radioligands for imaging the NR2B subunit within the NMDA receptor complex in rats","author":"Cai","year":"2020","journal-title":"J. Nucl. Med."},{"issue":"3","key":"10.1016\/j.bbr.2020.113004_bib0645","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2967\/jnumed.113.130641","article-title":"Initial evaluation of 18F-GE-179, a putative PET Tracer for activated N-methyl D-aspartate receptors","volume":"55","author":"McGinnity","year":"2014","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.bbr.2020.113004_bib0650","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13550-020-00716-z","article-title":"In vivo glucose metabolism and glutamate levels in mGluR5 knockout mice: a multimodal neuroimaging study using [(18)F]FDG microPET and MRS","volume":"10","author":"Joo","year":"2020","journal-title":"EJNMMI Res."},{"issue":"2","key":"10.1016\/j.bbr.2020.113004_bib0655","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.nucmedbio.2005.12.001","article-title":"Ketamine displaces the novel NMDA receptor SPET probe [(123)I]CNS-1261 in humans in vivo","volume":"33","author":"Stone","year":"2006","journal-title":"Nucl. Med. Biol."},{"issue":"3","key":"10.1016\/j.bbr.2020.113004_bib0660","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00213-007-1047-x","article-title":"Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: a [(123)I]CNS-1261 SPET study","volume":"197","author":"Stone","year":"2008","journal-title":"Psychopharmacology (Berl.)"},{"issue":"1","key":"10.1016\/j.bbr.2020.113004_bib0665","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.biopsych.2005.03.016","article-title":"Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo","volume":"58","author":"Bressan","year":"2005","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.bbr.2020.113004_bib0670","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/sj.mp.4001751","article-title":"First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients","volume":"11","author":"Pilowsky","year":"2006","journal-title":"Mol. Psychiatry"},{"issue":"7183","key":"10.1016\/j.bbr.2020.113004_bib0675","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature06612","article-title":"Identification of a serotonin\/glutamate receptor complex implicated in psychosis","volume":"452","author":"Gonzalez-Maeso","year":"2008","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bbr.2020.113004_bib0680","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/npr2.12068","article-title":"Regulatory system of mGluR group II in the nucleus accumbens for methamphetamine-induced dopamine increase by the medial prefrontal cortex","volume":"39","author":"Haddar","year":"2019","journal-title":"Neuropsychopharmacol. Rep."},{"issue":"1","key":"10.1016\/j.bbr.2020.113004_bib0685","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2174\/09298673113209990217","article-title":"In vivo imaging of the metabotropic glutamate receptor 1 (mGluR1) with positron emission tomography: recent advance and perspective","volume":"21","author":"Li","year":"2014","journal-title":"Curr. Med. Chem."},{"issue":"3","key":"10.1016\/j.bbr.2020.113004_bib0690","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.bmc.2018.12.025","article-title":"Synthesis and evaluation of 4-(2-fluoro-4-[(11)C]methoxyphenyl)-5-((2-methylpyridin-4-yl)methoxy)picolinamide for PET imaging of the metabotropic glutamate receptor 2 in the rat brain","volume":"27","author":"Kumata","year":"2019","journal-title":"Bioorg. Med. Chem."},{"issue":"8","key":"10.1016\/j.bbr.2020.113004_bib0695","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/jcbfm.2010.65","article-title":"In vivo and in vitro validation of reference tissue models for the mGluR(5) ligand [(11)C]ABP688","volume":"30","author":"Elmenhorst","year":"2010","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.bbr.2020.113004_bib0700","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2016.11.008","article-title":"Metabotropic glutamate receptor 5 neuroimaging in schizophrenia","volume":"183","author":"Akkus","year":"2017","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.bbr.2020.113004_bib0705","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1503\/jpn.130242","article-title":"Metabotropic glutamate receptor mGluR2\/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics","volume":"39","author":"Matosin","year":"2014","journal-title":"J. Psychiatry Neurosci."},{"issue":"22","key":"10.1016\/j.bbr.2020.113004_bib0710","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24224190","article-title":"A survey of molecular imaging of opioid receptors","volume":"24","author":"Cumming","year":"2019","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.bbr.2020.113004_bib0715","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1038\/s41467-019-12366-4","article-title":"Reduced mu opioid receptor availability in schizophrenia revealed with [(11)C]-carfentanil positron emission tomographic Imaging","volume":"10","author":"Ashok","year":"2019","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.bbr.2020.113004_bib0720","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.euroneuro.2004.10.001","article-title":"Histamine H1 receptors in schizophrenic patients measured by positron emission tomography","volume":"15","author":"Iwabuchi","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.bbr.2020.113004_bib0725","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/0271678X17748786","article-title":"Sifting through the surfeit of neuroinflammation tracers","volume":"38","author":"Cumming","year":"2018","journal-title":"J. Cereb. Blood Flow Metab."},{"issue":"13","key":"10.1016\/j.bbr.2020.113004_bib0730","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1017\/S0033291718003057","article-title":"Neuroinflammation in schizophrenia: meta-analysis of in vivo microglial imaging studies","volume":"49","author":"Marques","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.bbr.2020.113004_bib0735","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbi.2018.11.318","article-title":"State-associated changes in longitudinal [(18)F]-PBR111 TSPO PET imaging of psychosis patients: Evidence for the accelerated ageing hypothesis?","volume":"77","author":"De Picker","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbr.2020.113004_bib0740","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.schres.2018.10.008","article-title":"Preliminary data indicating a connection between stress-induced prefrontal dopamine release and hippocampal TSPO expression in the psychosis spectrum","volume":"213","author":"Schifani","year":"2019","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.bbr.2020.113004_bib0745","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1503\/jpn.170201","article-title":"GABA levels and TSPO expression in people at clinical high risk for psychosis and healthy volunteers: a PET-MRS study","volume":"44","author":"Da Silva","year":"2019","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.bbr.2020.113004_bib0750","doi-asserted-by":"crossref","DOI":"10.1177\/1536012118792317","article-title":"Emerging PET radiotracers and targets for imaging of neuroinflammation in neurodegenerative diseases: outlook beyond TSPO","volume":"17","author":"Narayanaswami","year":"2018","journal-title":"Mol. Imaging"},{"issue":"3","key":"10.1016\/j.bbr.2020.113004_bib0755","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.neuroimage.2010.11.015","article-title":"Where in-vivo imaging meets cytoarchitectonics: the relationship between cortical thickness and neuronal density measured with high-resolution [18F]flumazenil-PET","volume":"56","author":"la Fougere","year":"2011","journal-title":"Neuroimage"},{"issue":"11","key":"10.1016\/j.bbr.2020.113004_bib0760","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1176\/appi.ajp.2015.14081031","article-title":"In vivo measurement of GABA transmission in healthy subjects and schizophrenia patients","volume":"172","author":"Frankle","year":"2015","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.bbr.2020.113004_bib0765","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/schbul\/sbt052","article-title":"Reduced binding potential of GABA-A\/benzodiazepine receptors in individuals at ultra-high risk for psychosis: an [18F]-fluoroflumazenil positron emission tomography study","volume":"40","author":"Kang","year":"2014","journal-title":"Schizophr. Bull."},{"issue":"1\u20133","key":"10.1016\/j.bbr.2020.113004_bib0770","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.schres.2010.12.025","article-title":"Deficits in GABA(B) receptor system in schizophrenia and mood disorders: a postmortem study","volume":"128","author":"Fatemi","year":"2011","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.bbr.2020.113004_bib0775","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1021\/acschemneuro.8b00038","article-title":"Synthesis and evaluation of a new (18)F-Labeled radiotracer for studying the GABAB receptor in the mouse brain","volume":"9","author":"Naik","year":"2018","journal-title":"ACS Chem. Neurosci."},{"issue":"3","key":"10.1016\/j.bbr.2020.113004_bib0780","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1017\/S1092852918001013","article-title":"Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate","volume":"23","author":"Stahl","year":"2018","journal-title":"CNS Spectr."},{"issue":"7","key":"10.1016\/j.bbr.2020.113004_bib0785","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jamapsychiatry.2016.0442","article-title":"Nature of glutamate alterations in schizophrenia: a meta-analysis of proton magnetic resonance spectroscopy studies","volume":"73","author":"Merritt","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"26","key":"10.1016\/j.bbr.2020.113004_bib0790","doi-asserted-by":"crossref","first-page":"9615","DOI":"10.1523\/JNEUROSCI.0329-15.2015","article-title":"Prefrontal and striatal glutamate differently relate to striatal dopamine: potential regulatory mechanisms of striatal presynaptic dopamine function?","volume":"35","author":"Gleich","year":"2015","journal-title":"J. Neurosci."},{"issue":"10","key":"10.1016\/j.bbr.2020.113004_bib0795","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S2215-0366(18)30268-2","article-title":"The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: a cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study","volume":"5","author":"Jauhar","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"11","key":"10.1016\/j.bbr.2020.113004_bib0800","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1038\/npp.2017.67","article-title":"Presynaptic dopamine synthesis capacity in schizophrenia and striatal blood flow change during antipsychotic treatment and medication-free conditions","volume":"42","author":"Eisenberg","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.bbr.2020.113004_bib0805","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/jamaneurol.2018.1836","article-title":"Assessing synaptic density in alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.bbr.2020.113004_bib0810","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41467-019-14122-0","article-title":"Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats","volume":"11","author":"Onwordi","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbr.2020.113004_bib0815","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1172\/JCI123743","article-title":"PET neuroimaging reveals histone deacetylase dysregulation in schizophrenia","volume":"129","author":"Gilbert","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bbr.2020.113004_bib0820","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41398-020-00911-5","article-title":"In vivo human brain expression of histone deacetylases in bipolar disorder","volume":"10","author":"Tseng","year":"2020","journal-title":"Transl. Psychiatry"}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432820307038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432820307038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T13:24:52Z","timestamp":1759065892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432820307038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":164,"alternative-id":["S0166432820307038"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2020.113004","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular imaging of schizophrenia: Neurochemical findings in a heterogeneous and evolving disorder","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2020.113004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113004"}}